Sanofi
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
FDA lifts pause on Novavax flu vaccine trials
The FDA has lifted the clinical hold on Novavax's COVID-19 and influenza combination vaccine trials, allowing Phase 3 testing to resume after addressing concerns. The hold was due to a serious adverse event initially classified as motor neuropathy, later determined to be ALS, unrelated to the vaccine. Novavax aims to capitalize on a protein-based alternative to mRNA vaccines, despite market challenges.
AI In Precision Medicine Market : Future Industry Scope, Growth
AI In Precision Medicine Market to grow at a High CAGR from 2024-2031, driven by AI's ability to tailor treatments based on genetic, environmental, and lifestyle factors. Key players include IBM, Microsoft, AstraZeneca, and Siemens Healthineers. Market segments include technology, component, application, and region.
AstraZeneca, Amgen Claim Late-Stage Win in Chronic Rhinosinusitis but Analyst Flags ...
AstraZeneca and Amgen's Tezspire met primary endpoint in Phase III WAYPOINT study, showing significant efficacy in chronic rhinosinusitis with nasal polyps. Tezspire reduced nasal polyps size and congestion with a consistent safety profile. Analysts note potential regulatory risks due to single study evaluation, contrasting with Sanofi and Regeneron's Dupixent, which had two pivotal studies. AstraZeneca and Amgen plan to share data with regulatory authorities and present at a medical congress.
J&J bids to add smouldering myeloma to Darzalex label
Johnson & Johnson reports positive phase 3 data for Darzalex in smouldering multiple myeloma, filing applications in Europe and US. Darzalex Faspro, a subcutaneous injection, could be the first treatment option for this pre-cancerous condition. Based on AQUILA study results, Darzalex Faspro showed significant PFS reduction and ORR improvement compared to active monitoring. Darzalex, already a $9.7 billion drug, aims to maintain its lead over Sanofi's Sarclisa in the multiple myeloma market.
Hold Recommendation for Vir Biotechnology Amid Cautious Optimism on Infectious Disease
J.P. Morgan analyst Eric Joseph maintains a Hold rating on Vir Biotechnology (VIR) stock, balancing cautious optimism about its infectious disease treatments and oncology assets, with a focus on upcoming phase 2 trial results.
Decoding Revolution Medicines Inc (RVMD): A Strategic SWOT Insight
Revolution Medicines Inc (NASDAQ:RVMD) leads in precision oncology with a $1.5 billion deficit, strategic partnerships, and a robust pipeline, facing market competition and regulatory challenges.
Tezspire succeeds in Phase III nasal polyps trial
AstraZeneca and Amgen's Tezspire met co-primary endpoints in a Phase III trial for chronic rhinosinusitis with nasal polyps, showing significant reduction in nasal polyps and congestion. Tezspire, a TSLP inhibiting monoclonal antibody, also received FDA breakthrough therapy designation for COPD. The therapy competes with Sanofi and Regeneron's Dupixent, which generated €10.7bn in sales in 2022. Both Tezspire and Dupixent are projected to see increased sales by 2030.
Patient Recruitment for Rare Disease Trials Summit
The Patient Recruitment for Rare Disease Trials Summit tackles challenges like geographical dispersion and low awareness by exploring innovative strategies to efficiently identify and engage eligible participants, featuring actionable insights, knowledge on patient feedback integration, best practices for data sharing, and fair patient reimbursement discussions.
CervoMed Awarded the Prix Galien USA 2024 Prize for Best Startup
CervoMed Inc. wins Prix Galien USA 2024 Best Startup award for developing potential treatment for Dementia with Lewy bodies (DLB), a condition affecting over 1.4 million patients in the U.S. and EU. The company's drug, neflamapimod, is in Phase 2b clinical trial, with topline results expected in December 2024.
Expert Comments on the Risks and Benefits of Tirzepatide Following the Death of Susan McGowan
Experts discuss tirzepatide's safety and benefits after a UK death linked to the drug, highlighting the need for high-quality trials and the importance of the 'yellow card scheme' for reporting side effects.
© Copyright 2024. All Rights Reserved by MedPath